Inhibrx, Inc. - stock earnings
INBX Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -93.6 million USD | 1.6 million USD |
| 2023Q3 | -51.8 million USD | 119000 USD |
| 2023Q2 | -47.1 million USD | 30000 USD |
| 2023Q1 | -48.7 million USD | 17000 USD |
| 2022Q4 | -40.9 million USD | 274000 USD |
| 2022Q3 | -40.6 million USD | 278000 USD |
| 2022Q2 | -37.7 million USD | 711000 USD |
| 2022Q1 | -33.5 million USD | 915000 USD |
| 2021Q4 | -21.2 million USD | 2.8 million USD |
| 2021Q3 | -20.6 million USD | 2.5 million USD |
| 2021Q2 | -20.7 million USD | 918000 USD |
| 2021Q1 | -19.3 million USD | 863000 USD |
| 2020Q4 | -17.6 million USD | 2.8 million USD |
| 2020Q3 | -20.5 million USD | 5.8 million USD |
| 2020Q2 | -17.9 million USD | 3.3 million USD |
| 2020Q1 | -20.1 million USD | 872000 USD |
| 2019Q4 | -16.3 million USD | 267000 USD |
| 2019Q3 | -20.2 million USD | 794000 USD |
| 2019Q2 | -11.1 million USD | 1.0 million USD |
| 2019Q1 | -3.8 million USD | 7.0 million USD |
| 2018Q2 | -7.2 million USD | 2.5 million USD |
| 2018Q1 | -9.4 million USD | 2.5 million USD |
INBX Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -241.4 million USD | 1.8 million USD |
| 2022 | -145.2 million USD | 2.2 million USD |
| 2021 | -81.8 million USD | 7.1 million USD |
| 2020 | -75.6 million USD | 12.8 million USD |
| 2019 | -51.4 million USD | 9.1 million USD |
| 2018 | -31.2 million USD | 7.5 million USD |
| 2017 | -19.4 million USD | 8.0 million USD |
INBX
Price: $34.01
52 week price:
Earnings Per Share: -5.12 USD
P/E Ratio: -8.80
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 275430
Market Capitalization: 1.7 billion